z-logo
open-access-imgOpen Access
Summary of 2021 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans
Publication year - 2021
Publication title -
infection and chemotherapy/gam'yeom gwa hwahag yo'beob/infection and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.724
H-Index - 26
eISSN - 2092-6448
pISSN - 1598-8112
DOI - 10.3947/ic.2021.0305
Subject(s) - medicine , human immunodeficiency virus (hiv) , tuberculosis , intensive care medicine , clinical research , epidemiology , antiretroviral treatment , antiretroviral therapy , pediatrics , immunology , family medicine , viral load , pathology
Since the establishment of the Committee for Clinical Guidelines for the Diagnosis and Treatment of human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) by the Korean Society for AIDS in 2010, clinical guidelines have been prepared in 2011, 2013, 2015, and 2018. As new research findings on the epidemiology, diagnosis, and treatment of AIDS have been published in and outside of Korea along with the development and introduction of new antiretroviral medications, a need has arisen to revise the clinical guidelines by analyzing such new data. The clinical guidelines address the initial evaluation of patients diagnosed with HIV/AIDS, follow-up tests, appropriate timing of medication, appropriate antiretroviral medications, treatment strategies for patients who have concurrent infections with hepatitis B or C virus, recommendations for resistance testing, treatment for patients with HIV and tuberculosis coinfections, and treatment in pregnant women. Through these clinical guidelines, the Korean Society for AIDS and the Committee for Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS contributes to overcoming AIDS by delivering latest data and treatment strategies to healthcare professionals who treat AIDS in the clinic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here